Fact sheet: Polar Capital HcarBluChp

Fund information
Fund name
Polar Capital Healthcare Blue Chip I Acc USD
Fund manager company
Polar Capital
Fund type
OEIC
Fund managers
  • Gareth Powellsince 11/09/2014
  • Dan Mahonysince 11/09/2014
Fund objective
The Fund aims to achieve long-term capital appreciation by investing in a globally diversified portfolio of healthcare companies.
Benchmark
  • MSCI World Daily Health Care Index
Investment style
Active
Investment method
Shares
Quick stats
1 Year return
-5.9%
1 Year rank in sector
-
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.02%
Fund size
£46m (£54m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
120
Top in this sector
Fund name1 Year
Pictet Health4.9%
Fidelity Gbl Health Care4.2%
BB Medtech4%
Variopartner SICAV MVGbMdtcF3.4%
Variopartner SICAV SEmMkHcare-0.5%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA56.3%
    Ireland9.5%
    Germany9.3%
    Switzerland7.9%
    Money Market7.1%
  • Pharmaceuticals28.2%
    Biotechnology/Medical22.3%
    Healthcare & Medical Products20.1%
    Health Care18.8%
    Money Market7.1%
  • US Equities55.9%
    Swiss Equities14.3%
    Irish Equities9.6%
    German Equities7.9%
    UK Equities4.6%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund-0.7%-8.1%-7.5%-5.9%--
Sector0.5%-6.2%-3.4%-9.5%23.9%107.7%
Rank within sector------
Quartile
Calendar performance
 YTD - 20162015201420132012
Fund-6.6%1.2%---
Sector-11.2%7.2%28.1%41%16.7%
Rank within sector-----
Quartile
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
-
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
-
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
-
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
-
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
-
Price movement
52 week high11.17
52 week low9.41
Current bid price-
Current offer price-
Current mid price9.97
Region
1USA56.34%
2Ireland9.47%
3Germany9.26%
4Switzerland7.94%
5Money Market7.07%
6UK4.23%
7Israel3.64%
8Denmark2.05%
Industry sector
1Pharmaceuticals28.24%
2Biotechnology/Medical22.31%
3Healthcare & Medical Products20.08%
4Health Care18.82%
5Money Market7.07%
6Food & Drug Retailers3.49%
Asset type
1US Equities55.9%
2Swiss Equities14.3%
3Irish Equities9.6%
4German Equities7.9%
5UK Equities4.6%
6Israeli Equities3.7%
7Danish Equities2%
8Money Market2%
Individual holdings
1MEDTRONIC PLC6.35%
2PFIZER INC6.19%
3FRESENIUS MEDICAL CARE AG & CO.KGAA6.15%
4MERCK & CO INC(NEW)4.81%
5ASTRAZENECA PLC4.23%
6ROCHE HLDG AG4.22%
7BECTON DICKINSON & CO4.15%
8INCYTE CORP4.13%
9ACTELION3.72%
Management
Fund manager group
Polar Capital
Fund manager company
Polar Capital
Fund type
OEIC
Fund objective
The Fund aims to achieve long-term capital appreciation by investing in a globally diversified portfolio of healthcare companies.
Benchmark
  • MSCI World Daily Health Care Index
Investment style
Active
Investment method
Shares
Fund managers
NameSinceBiography
Gareth Powell11/09/2014Gareth joined Polar Capital in 2007 to set up the healthcare team. He has over 15 years’ investment experience in the healthcare sector, with 11 years as a Portfolio Manager. He joined Framlington in 1999 becoming a Portfolio Manager on the Framlington health fund. In 2002, he helped launch and then run the Framlington biotech fund. Gareth became a CFA charterholder in 2003. Gareth studied biochemistry at Oxford from 1995 to 1999 and during that time worked at Astellas, the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and the Oxford Business School.
Dan Mahony11/09/2014Daniel joined Polar Capital to set up the healthcare team in 2007. He has 23 years of industry experience, comprising more than 16 years’ investment experience in the healthcare sector, with over seven years as a Portfolio Manager and nine years as a sell-side analyst. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991.
Compliance
Transparent for Austrian Tax, IA Recognised, Reporting Fund Status, UCITS IV Compliant, UCITS V Compliant
Domicile
No data available.
Fund for sale in
Austria, Belgium, Germany, Denmark, Spain, Finland, France, United Kingdom, Guernsey, Ireland, Italy, Jersey, Luxembourg, Netherlands, Norway, Offshore, Singapore, Sweden
Polar Capital Healthcare Blue Chip I Acc EUR
Initial charge5%
Annual charge0.85%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.02%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.26
CurrencyEUR
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeKQIC
Polar Capital Healthcare Blue Chip I Acc GBP
Initial charge5%
Annual charge0.85%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.02%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price7.91
CurrencyGBP
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeKQIE
Polar Capital Healthcare Blue Chip I Acc USD
Initial charge5%
Annual charge0.85%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.02%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.97
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeKQIG
Polar Capital Healthcare Blue Chip I Inc EUR
Initial charge5%
Annual charge0.85%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.02%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.14
CurrencyEUR
Price updated07/12/2016
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeKQID
Polar Capital Healthcare Blue Chip I Inc GBP
Initial charge5%
Annual charge0.85%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.02%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price7.8
CurrencyGBP
Price updated07/12/2016
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeKQIF
Polar Capital Healthcare Blue Chip I Inc USD
Initial charge5%
Annual charge0.85%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.02%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.84
CurrencyUSD
Price updated07/12/2016
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeKQIH
Polar Capital Healthcare Blue Chip S Acc GBP
Initial charge5%
Annual charge0.7%
Min single investment£5,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.87%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price7.93
CurrencyGBP
Price updated07/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeKQII
Polar Capital Healthcare Blue Chip S Acc USD
Initial charge5%
Annual charge0.7%
Min single investment£5,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.87%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.99
CurrencyUSD
Price updated07/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeKQIK
Polar Capital Healthcare Blue Chip S Hedged Inc GBP
Initial charge-
Annual charge0.65%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price-
CurrencyGBX
Price updated01/01/1900
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeNMEC
Polar Capital Healthcare Blue Chip S Inc GBP
Initial charge5%
Annual charge0.7%
Min single investment£5,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.87%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price7.82
CurrencyGBP
Price updated07/12/2016
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeKQIJ
Polar Capital Healthcare Blue Chip S Inc USD
Initial charge5%
Annual charge0.7%
Min single investment£5,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.87%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price9.87
CurrencyUSD
Price updated07/12/2016
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeKQIL
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.